Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.04 USD | -4.65% |
|
+90.48% | +78.51% |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|
Net sales 1 | 7.787 | 3.988 | 2.437 | 0.0222 |
EBITDA | - | -3.252 | -1.882 | -0.1049 |
EBIT 1 | -0.5623 | -3.253 | -1.886 | -0.1097 |
Operating Margin | -7.22% | -81.57% | -77.4% | -493.02% |
Earnings before Tax (EBT) 1 | -0.7817 | -4.72 | -2.224 | -0.5712 |
Net income 1 | -0.7817 | -4.72 | -2.224 | -0.5712 |
Net margin | -10.04% | -118.37% | -91.26% | -2,567.87% |
EPS 2 | -0.0224 | -0.1338 | -0.0587 | -0.002066 |
Free Cash Flow | - | -2.371 | -1.251 | - |
FCF margin | - | -59.46% | -51.31% | - |
FCF Conversion (EBITDA) | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - |
Dividend per Share | - | - | - | - |
Announcement Date | 23/02/23 | 23/02/23 | 03/01/24 | 12/04/24 |
Balance Sheet Analysis
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|
Net Debt 1 | 0.68 | 2.62 | 1.01 | 0.23 |
Net Cash position 1 | - | - | - | - |
Leverage (Debt/EBITDA) | - | -0.8069 x | -0.5363 x | -2.149 x |
Free Cash Flow | - | -2.37 | -1.25 | - |
ROE (net income / shareholders' equity) | - | 179% | 88% | 270% |
ROA (Net income/ Total Assets) | - | -107% | -66.4% | -151% |
Assets 1 | - | 4.413 | 3.351 | 0.3783 |
Book Value Per Share 2 | -0.0600 | -0.0900 | -0.0500 | -0 |
Cash Flow per Share 2 | 0.0200 | 0.0200 | 0.0200 | - |
Capex | - | 0.03 | - | - |
Capex / Sales | - | 0.79% | - | - |
Announcement Date | 23/02/23 | 23/02/23 | 03/01/24 | 12/04/24 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
1st Jan change | Capi. | |
---|---|---|
+78.51% | 4.01Cr | |
-7.04% | 18TCr | |
-6.17% | 9.92TCr | |
-6.19% | 6.63TCr | |
-10.73% | 4.47TCr | |
+7.80% | 4.38TCr | |
+10.35% | 4.2TCr | |
+11.33% | 2.9TCr | |
+16.18% | 2.41TCr | |
-8.67% | 2.35TCr |
- Stock Market
- Equities
- BRGX Stock
- Financials BioRegenx, Inc.